DUO-MEDIHALER
LOE Approachingisoproterenol hydrochloride; phenylephrine bitartrate
NDAINHALATIONAEROSOL, METERED
Approved
Aug 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DUO-MEDIHALER (isoproterenol hydrochloride; phenylephrine bitartrate). Approved for to improve hemodynamic status. First approved in 1973.
Drug data last refreshed 12h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUO-MEDIHALER is a combination inhaled aerosol containing isoproterenol hydrochloride (a beta-adrenergic agonist) and phenylephrine bitartrate (an alpha-adrenergic agonist) approved in 1973. It is indicated to improve hemodynamic status via inhalation delivery, combining bronchodilation and vasopressor effects.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on cost management and niche retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on DUO-MEDIHALER offers limited career growth and advancement opportunities due to its LOE-approaching status and minimal linked job postings (0). This role is best suited for professionals seeking stable, maintenance-focused work in a legacy product rather than high-visibility launch or expansion projects.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.